This trial is terminated!
Search for a recruiting clinical trial for your condition
Your journey
1What's a trial
4Get in touch
More info
You can access this
clinical trial
if you have
Plaque Psoriasis
and you are
over 18
years old
This is an early phase trial to investigate
how or whether the drug affects your body.
Show me locations

The purpose

IFN-gamma is a central player in the development of psoriasis lesions, which can be involved a variety of cellular processes in the skin. Dendritic cells are important cells in driving inflammation in psoriasis through the induction of T cells that produce IL-17 in psoriasis. Injecting IFN-g into the skin can increase the numbers of T cells and also inflammatory DCs that produce cytokines involved in IL-17 production. Thus, the investigators hypothesize that the dendritic cells present in the skin after IFN-g injection polarize IL-17-producing T cells.

Provided treatments

  • Drug: Actimmune

Locations near you

Unfortunately, there are no recruiting locations near you. Please check the list with all locations below.
Tris trial is registered with FDA with number: NCT01317017. The sponsor of the trial is Rockefeller University and it is looking for 2 volunteers for the current phase.
Official trial title:
Cellular Responses To Intradermal-Gamma (IFN-gamma) in Normal and Psoriatic Patients